Biocept Inks Research Pact With Protean BioDiagnostics For Target Selector Kit Advantages In Lung Cancer

By Vandana Singh5 days ago

  • Biocept Inc (NASDAQ: BIOC) will collaborate with Protean BioDiagnostics Inc to research Biocept's Target Selector molecular assay's ability to determine EGFR status in non-small cell lung ...

Full story available on Benzinga.com

Continue read on benzinga.com